Last Updated on October 10, 2024 by The Health Master
Drug major Lupin Limited (Lupin) has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), efinaconazole topical solution, 10% to market a generic equivalent of Jublia topical solution, 10%, of Bausch Health Americas, Inc.
The product will be manufactured at Lupin’s facility in Pithampur, India.
Efinaconazole topical solution, 10% (RLD: Jublia topical solution, 10%) had estimated annual sales of US$ 274 million in the US (IQVIA MAT December 2021).
USFDA gives nod to Lupin for Sevelamer Hydrochloride Tablets, 800 mg
USFDA approves this drug for bone marrow cancer treatment
USFDA gives nod to Unichem Laboratories for Divalproex Sodium
USFDA approves this drug for all heart patients to cut death, hospitalization risk
USFDA gives nod to Zydus to market Dapagliflozin tablets
USFDA gives nod to Strides Pharma for Amantadine HCL Softgel Capsules
Govt listed 213 drugs for which procurement agencies could not find local manufacturers
USFDA gives nod to Lupin for Sevelamer Hydrochloride Tablets, 800 mg
USFDA declines to approve Gilead’s HIV drug on this concern
Why these Pharma Companies are realigning their India operations
USFDA approves this drug for bone marrow cancer treatment
NDPS Exporters and Importers to register with ICEGATE portal: CBN
USFDA gives nod to Unichem Laboratories for Divalproex Sodium
20 projects worth Rs. 840 crore for PLI scheme for Bulk drugs
Drug recall: Aurobindo, Sun Pharma recall these products
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
